USF Health Is Studying Psychedelic Treatments for Depression, Anxiety and PTSD

Psychedelic medicine research is no longer happening only in California laboratories, underground therapy circles or documentaries narrated by people whispering about consciousness.

It is happening right here in Tampa.

The University of South Florida’s Department of Psychiatry and Behavioral Neurosciences is conducting clinical trials investigating psychedelic medications as potential treatments for serious mental health conditions. Researchers are studying how psilocybin and related compounds affect the brain, how long their therapeutic effects may last and what side effects can occur.

For Tampa Bay, this is a significant development. It places psychedelic research inside one of Florida’s major medical institutions and brings the conversation closer to patients, families and health care professionals in our community.

What Is USF Health Studying?

According to USF Health, researchers are examining how psilocybin and similar psychedelic compounds interact with serotonin receptors and may help the brain form new neural pathways.

These pathways are important because many psychiatric conditions involve deeply established patterns of thought, emotion and behavior. Researchers want to understand whether psychedelic medications, when combined with professional support, can temporarily create greater psychological flexibility.

The goal is not simply to give someone a psychedelic drug and hope for a miracle. These are carefully controlled clinical trials involving:

• Medical screening
• Psychiatric evaluations
• Physical examinations
• Laboratory testing
• Supervised dosing sessions
• Therapeutic guidance
• Long-term monitoring
• Documentation of benefits and potential side effects

That distinction matters. Psychedelic-assisted therapy is being studied as a structured medical process—not as a conventional prescription someone takes home and uses without supervision.

Which Mental Health Conditions Are Included?

USF Health’s current research program includes psychedelic studies connected to several difficult-to-treat psychiatric conditions.

Treatment-Resistant Depression

One USF study is examining an investigational psychedelic medication in adults with treatment-resistant depression.

Treatment-resistant depression generally describes depression that has not adequately improved after multiple established treatments. For patients who have tried medications, therapy or other interventions without meaningful relief, new treatment options are desperately needed.

The study is designed to evaluate the medication’s safety, effectiveness and tolerability over five months under supportive conditions.

Generalized Anxiety Disorder

USF is also participating in a clinical trial evaluating RE104, an investigational psychedelic medication, for generalized anxiety disorder.

The study compares a single 30-milligram injection with a placebo. Participants undergo screening, a one-day treatment period and 84 days of follow-up observation.

Generalized anxiety disorder can involve persistent worry, restlessness, difficulty concentrating, disrupted sleep and physical tension. The possibility that one supervised psychedelic treatment could produce lasting improvement is compelling, but that possibility must be tested through rigorous research.

PTSD

Another USF clinical trial is studying COMP360, a proprietary formulation of synthetic psilocybin, in people with post-traumatic stress disorder.

Participants receive controlled doses during a double-blind phase followed by a longer open-label phase. Researchers will evaluate both safety and effectiveness over an extended period.

PTSD can be especially difficult to treat because trauma is not merely an unpleasant memory. It can affect a person’s nervous system, relationships, sleep, emotional regulation and sense of safety. Psychedelic-assisted therapy may eventually offer another tool for helping some patients process traumatic experiences, but the evidence is still developing.

Adjustment Disorder Associated With Medical Illness

USF is also studying an investigational psychedelic medication in people experiencing adjustment disorder related to serious medical conditions, including cancer, ALS, multiple sclerosis, Parkinson’s disease and idiopathic pulmonary fibrosis.

A life-changing diagnosis can cause intense anxiety, depression, grief and existential distress. Psychedelic medicine research has increasingly explored whether supervised psychedelic experiences can help patients confront illness and mortality with less fear and greater emotional acceptance.

How Might Psychedelics Help the Brain?

Classic psychedelics such as psilocybin primarily affect the brain’s serotonin system, particularly the 5-HT2A receptor.

Researchers believe these effects may temporarily change communication between brain networks and promote neuroplasticity—the brain’s ability to reorganize, adapt and form new connections.

In plain English, psychedelics may create a temporary window in which the brain becomes less stuck.

That does not mean the medicine automatically fixes depression, anxiety or trauma. A person can have a powerful experience without experiencing lasting therapeutic improvement. This is why preparation, supervision and integration are considered important parts of psychedelic-assisted treatment research.

The psychedelic experience may open the door, but patients and therapists still have to walk through it.

Why USF’s Research Matters for Florida

Florida has millions of residents experiencing depression, anxiety, PTSD, substance-use disorders and other mental health challenges. At the same time, access to effective psychiatric care remains limited for many communities.

Having psychedelic clinical trials at USF Health gives Florida patients an opportunity to participate in legitimate, carefully monitored research without traveling across the country.

It also helps move the public discussion beyond two unhelpful extremes.

Psychedelics are neither miracle cures nor simply dangerous drugs with no medical value. They are powerful substances with potential benefits, meaningful risks and a growing scientific record that deserves serious investigation.

Research allows us to replace assumptions with evidence.

It also helps answer the questions that must be resolved before psychedelic-assisted treatments can become widely available:

• Which conditions respond best?
• Which patients are appropriate candidates?
• What doses are safest and most effective?
• How important is psychotherapy?
• How long do the benefits last?
• What adverse effects can occur?
• Who should not receive psychedelic treatment?
• What training should facilitators and clinicians receive?

These questions cannot be answered through hype, fear or social media anecdotes. They require controlled trials and long-term observation.

Psychedelic Therapy Is Not the Same as Self-Medicating

The growing popularity of psychedelic medicine can sometimes make these treatments sound deceptively simple. Someone hears that psilocybin is being studied for depression and concludes that taking mushrooms alone must be the same thing.

It is not.

Clinical trials carefully screen participants because psychedelics may be inappropriate or risky for certain people. Some USF studies exclude individuals with conditions such as bipolar disorder, schizophrenia, psychotic disorders or borderline personality disorder. Other medical conditions and medications may also affect eligibility.

Participants receive measured doses in controlled environments with trained professionals present. Researchers then continue monitoring them after the acute psychedelic experience has ended.

That level of screening and support cannot be replicated by randomly eating something purchased from a stranger who describes himself as “basically a shaman.”

Could This Research Lead to FDA-Approved Psychedelic Treatments?

That is ultimately one of the goals.

USF researchers are collecting the clinical evidence regulators need to evaluate potential psychedelic treatments. This includes information about effectiveness, dosing, side effects, patient selection and long-term outcomes.

Dr. Ryan Wagoner, chair of USF Health’s Department of Psychiatry and Behavioral Neurosciences, said he hopes the research leads to another treatment option for people with significant psychiatric conditions.

That is the most responsible way to look at psychedelic medicine. These treatments may not replace every antidepressant, therapist or existing psychiatric intervention. They may eventually become another option—particularly for patients who have not responded to what is currently available.

Medicine rarely needs one universal cure. It needs more effective tools.

How Can Someone Learn About USF’s Psychedelic Clinical Trials?

People interested in participating should review the official USF Health clinical-trials page and contact the study coordinator associated with the appropriate trial.

Clinical-trial participation is not the same as receiving ordinary medical treatment. Every study has specific inclusion and exclusion requirements, and not every applicant will qualify.

Individuals should never discontinue prescribed medication or change an existing mental health treatment plan to qualify for a study without first speaking with a licensed health care professional.

The Bigger Picture

For years, psychedelic education has existed ahead of psychedelic access. That can be frustrating, but it is also necessary.

If psychedelic medicines eventually become part of mainstream mental health care, patients need accurate information about their potential benefits, limitations and risks. Clinicians need standardized training. Regulators need reliable data. Communities need safeguards that do not recreate the failures of either prohibition or poorly regulated commercialization.

USF Health’s research is one more indication that psychedelics have entered a serious new chapter.

The question is no longer whether researchers should study psychedelic medicine. Major universities and medical institutions are already doing it.

The questions now are what these treatments can genuinely accomplish, how they can be administered safely and which patients are most likely to benefit.

Those answers will come from science—not stigma, sales pitches or wishful thinking.

At Learn Euphoria, our mission is legalization through education. We believe honest psychedelic education must make room for both optimism and caution. Psychedelics may become important tools in mental health care, but responsible progress depends on research, informed consent, professional support and respect for the power of these substances.

The fact that this work is now happening at USF makes the future of psychedelic medicine feel much closer to home.

Frequently Asked Questions

Is USF studying psilocybin?

Yes. USF Health is participating in clinical research involving psilocybin and other investigational psychedelic medications. One listed study evaluates COMP360, a synthetic psilocybin formulation, for PTSD.

What conditions are included in USF’s psychedelic research?

USF’s listed psychedelic trials involve treatment-resistant depression, generalized anxiety disorder, PTSD and adjustment disorder associated with serious medical illnesses.

Can anyone join a USF psychedelic clinical trial?

No. Each trial has specific medical and psychiatric eligibility criteria. Interested individuals must complete a screening process before they can participate.

Are psychedelics FDA-approved for treating depression or PTSD?

Psilocybin is not currently FDA-approved as a treatment for depression, anxiety or PTSD. The medications discussed in these USF studies remain investigational.

Does psychedelic-assisted therapy involve professional supervision?

In clinical research, yes. Participants are screened, monitored and given psychedelic medications under controlled conditions with professional support.

Is taking mushrooms at home the same as psychedelic-assisted therapy?

No. Clinical psychedelic treatment involves standardized dosing, medical screening, supervision, therapeutic support and follow-up monitoring. Unsupervised use does not provide those safeguards.

This article is for educational purposes only and does not provide medical advice. Psychedelic substances may carry significant medical, psychological and legal risks. Do not begin, discontinue or change any treatment without consulting a qualified health care professional.